Navigation Links
Corgenix to Exhibit AspirinWorks(R) Test at ACC.09
Date:3/18/2009

Test measures urinary 11dhTxB2 to assess aspirin effect

DENVER, March 18 /PRNewswire/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced it will be exhibiting its AspirinWorks(R) Test March 29 - 31 at the American College of Cardiology (ACC) 58th Annual Scientific Session. The annual meeting will take place in Orlando, Fla., at the Orange County Convention Center.

Corgenix representatives will be on-hand during ACC.09 at booth No. 1162 to answer questions about the AspirinWorks Test, including availability of the test, the latest supporting clinical data and ordering information. Complimentary AspirinWorks Tests will be offered to qualified attendees during regular exhibit hours March 29-31. Test results will be provided after the conference.

The AspirinWorks Test is the only FDA-cleared test that measures urinary 11dhTxB2 to accurately determine the effect of aspirin in apparently healthy individuals. 11dhTxB2 is a metabolite of thromboxane A2, the target of aspirin therapy.

"The phenomenon of aspirin effect has been validated in numerous randomized, controlled prospective outcome trials and demonstrates the value of understanding a patient's individual response to aspirin," said Gordon Ens, clinical director of Corgenix Medical Corporation. "The issue of 'aspirin resistance' is real, clinically important and deserves further examination. The ACC.09 conference presents an ideal environment in which to discuss the efficacy of this test."

The AspirinWorks Test was launched in the U.S. in June 2007 following FDA 510(k) clearance, and it is now available nationwide through major medical laboratories, including Quest, LabCorp and SpectraCell, as well as direct to consumers through HealthCheckUSA (www.HealthCheckUSA.com). The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin for prevention.

Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor's office or patient service center, making the test convenient for both physician and patient.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail: info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Corgenix Signs Technology Licensing Agreement With Japanese Government
2. Corgenix to Exhibit AspirinWorks(R) Test at ACC 2008 Meeting in Chicago
3. Corgenix Announces FDA Clearance for IgG Anti-AtherOx(R) Test Kit
4. Corgenix to Host Conference Call to Discuss Third Quarter Fiscal 2008 Results
5. Corgenix to Exhibit AspirinWorks(R) Test at ADA 2008 Meeting in San Francisco
6. Corgenix Expands Scientific Advisory Board
7. Corgenix to Host Conference Call to Discuss Fiscal 2008 Results
8. Corgenix Reports Fiscal 2008 Financial Results
9. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
10. Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting
11. Corgenix to Host Conference Call to Discuss First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... (PRWEB) , ... January 14, 2017 , ... ... a new service providing complete end-to-end genome assemblies to researchers around the globe. ... eliminates a major obstacle in answering a wide range of scientific questions. ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... an organic compound called fulvic acid that farms, greenhouses and hydroponics operations use ... cannabis are among the fastest growing segments of customers using this high grade ...
(Date:1/12/2017)... (PRWEB) , ... January 12, 2017 , ... Each year, ... Eureka Index – a process that evaluates the patent estate of a company, its ... LLC , a biomedical firm leading the way in technologies that transform energy sources ...
(Date:1/12/2017)... DC , January 12, 2017 ... up the world,s biggest facility for producing mycorrhizae. The ... the nutrient tapping potential of mycorrhizae and developed a ... ... (Logo: http://mma.prnewswire.com/media/456932/PRNE_TERI_Logo.jpg) The TERI facility ...
Breaking Biology Technology:
(Date:1/11/2017)... Intoxalock, a leading ignition interlock provider, has ... patent-pending calibration device. With this new technology, Intoxalock is ... data logs and process repairs at service center locations, ... drunk driving through the application of cutting-edge technologies is ... also for the customer who can get back on ...
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/6/2017)... Calif. , Jan. 5, 2017  Delta ID ... its iris scanning technology for automotive at CES® 2017. ... GNTX ) to demonstrate the use of iris ... identify and authenticate the driver in a car, and ... during the driving experience. Delta ID and ...
Breaking Biology News(10 mins):